Rocket Pharma falls after pulling US application for blood disorder gene therapy

Rocket Pharmaceuticals

03/10/2025 12:36

** Shares of Rocket Pharmaceuticals RCKT.O down 1.6% at $3.16 premarket

** Drug developer says it has withdrawn its application for potential U.S. approval of its experimental gene therapy, RP-L102, for a rare inherited blood disorder called Fanconi anemia

** RCKT says the move was driven by business strategy and not by concerns about safety or efficacy, and that it will consider external partnership opportunities for RP-L102

** Up to last close, stock down 74.5% YTD

 (Reporting by Puyaan Singh)

 ((Puyaan.Singh@thomsonreuters.com;))